About Edunn Biotechnology


Edunn Biotechnology, Inc. was incorporated in September 2005 and is the exclusive worldwide licensee of antisense CNS drugs from St. Louis University (SLU). These compounds comprise a totally new class of drugs to treat CNS conditions. Edunn is located at the Nidus Center for Scientific Enterprise in St. Louis, Missouri. Dr. Thomas Darling as the President and CEO has extensive experience managing R&D portfolios developing vaccines and biotech products for SmithKline Beecham, Searle, Pharmacia, and Pfizer. A Board of Directors and a Scientific Advisory Board have been established. The initial capitalization has been utilized to incorporate, improve and document intellectual property, perform further confirming pre-clinical studies, and develop a manufacturing process. Specific milestones were initiated and completed.

Edunn has made a tremendous amount of progress on validating the potential of its compound and with a modest sum of money could file its IND to enable clinical trials within one or two years. Accomplishments to date include:

  • The clinical advantages of the compound have been demonstrated.
  • The EDN-OL1 molecule has been demonstrated to cross the blood-brain barrier in mice, entering the brain after subcutaneous or intravenous injection.
  • The compound restores learning and memory in mice as well as restoring the normal efflux of amyloid protein and decreasing oxidative damage in the brain.
  • Restoration of cognitive function in three different mouse models occurs rapidly after only three doses of EDN-OL1. The rapid response is a distinguishing characteristic compared to competing drug candidates.
  • EDN-OL1 has the characteristics of a drug suitable for chronic administration.
  • The ease of manufacturing the compound has been validated.
  • A clear and direct path to FDA approval has been determined.

Edunn's business model is to encourage collaboration, partnering and investment discussions as OL-1 goes through safety and initial studies leading to Phase 1 clinical trials. Management believes the company can produce other CNS drug candidates from this platform. We believe Edunn's drug candidate presents an excellent opportunity given the large and growing number of Alzheimer's patients.